A novel human Fab antibody for Trop2 inhibits breast cancer growth <i>in vitro</i> and <i>in vivo</i>

Lin, Hong; Zhang, Huiling; Wang, Jun; Lu, Mei‐Ping; Zhao, Feng; Wang, Changjun; Tang, Xiaojun; Xu, Ning; Chen, Renjie; Zhang, Dawei; Zhao, Ping; Zhu, Jin; Yuan, Man; Feng, Zhenqing

doi:10.1002/ijc.28451

Cited by 75 publications

(78 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A few studies have suggested several molecular biomarkers of ovarian cancer2627. In our previous research, we have identified several oncogenic biomarkers, constructed related human monoclonal antibody-based drugs and tested their anti-tumor effectiveness28293031. Similarly, we have been searching a novel and valuable marker which associates with ovarian cancer and could be used as a potential candidate for targeted therapy with monoclonal antibodies.…”

Section: Discussionmentioning

confidence: 99%

ROR1 expression correlated with poor clinical outcome in human ovarian cancer

Zhang

Qiu

et al. 2014

Sci Rep

Self Cite

View full text Add to dashboard Cite

The receptor-tyrosine-kinase-like orphan receptor 1 (ROR1) is a transmembrane protein belongs to receptor tyrosine kinase (RTK) family. This study aimed to examine the expression of ROR1 in human ovarian cancer and investigate the relationship between its expression and the prognosis of ovarian cancer patients. In this present study, one-step quantitative reverse transcription-polymerase chain reaction (15 ovarian cancer samples of high FIGO stage, 15 ovarian cancer samples of low FIGO stage and nine normal ovary tissue samples) and immunohistochemistry by tissue microarrays (100 ovarian cancer samples and 50 normal ovary samples) were performed to characterize expression of the ROR1 gene in ovarian cancer. Kaplan-Meier survival and Cox regression analyses were executed to evaluate the prognosis of ovarian cancer. The results of qPCR and IHC analysis showed that the expression of ROR1 in ovarian cancer was significantly higher than that in normal ovary tissues (all p < 0.05). Survival analysis showed that ROR1 protein expression was one of the independent prognostic factors for disease-free survival and overall survival (both p < 0.05). The data suggest that ROR1 expression is correlated with malignant attributes of ovarian cancer and it may serve as a novel prognostic marker in ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

ROR1 expression correlated with poor clinical outcome in human ovarian cancer

Zhang

Qiu

et al. 2014

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…TMA was cut into 4-μm sections and placed on super frost charged glass microscope slides. IHC analysis was performed as previously described [23–25]. Deparaffinized sections (4 μm thick) from array blocks were separately stained on an Autostainer Universal Staining System (LabVision, Kalamazoo, MI, USA) using mouse anti-Rab27A antibody (1:100, Abcam, Cambridge, UK).…”

Section: Methodsmentioning

confidence: 99%

High Rab27A expression indicates favorable prognosis in CRC

Shi

Yang

et al. 2015

Diagn Pathol

View full text Add to dashboard Cite

BackgroundRab27A is a peculiar member in Rab family and has been suggested to play essential roles in the development of human cancers. However, the association between Rab27A expression and clinicopathological characteristics of colorectal cancer (CRC) has not been elucidated yet.MethodsOne-step quantitative real-time polymerase chain reaction (qPCR) test with 18 fresh-frozen CRC samples and immunohistochemistry (IHC) analysis in 112 CRC cases were executed to evaluate the relationship between Rab27A expression and the clinicopathological features of CRC. Cox regression and Kaplan-Meier survival analyses were performed to identify the prognostic factors for 112 CRC patients.ResultsThe results specified that the expression levels of Rab27A mRNA and protein were significantly higher in CRC tissues than that in matched non-cancerous tissues, in both qPCR test (p = 0.029) and IHC analysis (p = 0.020). The IHC data indicated that the Rab27A protein expression in CRC was statistically correlated with lymph node metastasis (p = 0.022) and TNM stage (p = 0.026). Cox multi-factor analysis and Kaplan-Meier method suggested Rab27A protein expression (p = 0.012) and tumor differentiation (p = 0.004) were significantly associated with the overall survival of CRC patients.ConclusionThe data indicated the differentiate expression of Rab27A in CRC tissues and matched non-cancerous tissues. Rab27A may be used as a valuable prognostic biomarker for CRC patients.

show abstract

“…Over-expression of TROP-2, which is accepted as an oncogene, is known as a poor prognostic indicator for various types of cancer, and makes TROP-2 a target molecule in treatment [13]. Furthermore, reduction was observed in the invasiveness of tumor cells by usage of antibodies developed against TROP-2 in breast and colon cancer [31,32].…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19

Mürtezaoğlu¹,

Güçer²

2017

pjp

View full text Add to dashboard Cite

In this study, we compared the diagnostic value of TROP-2 expression in distinguishing between benign and malignant thyroid lesions to those of HBME-1, CK19 and galectin-3. We selected 102 cases from our archive including 20 normal thyroid tissues, 23 follicular nodular diseases, 17 follicular adenomas, 20 follicular variant papillary carcinomas and 22 classical variant papillary carcinomas. Tissue microarrays constructed from these cases were immunohistochemically analyzed with HBME-1, CK19, galectin-3 and TROP-2. Respectively 73.8%, 83.3%, 69% and 50% of all papillary carcinomas were positive with HBME-1, CK19, galectin-3 and TROP-2. CK19 was positive respectively by 100%, 43.5% and 35.3% in cases of normal thyroid, follicular nodular diseases and follicular adenoma, while the other markers were negative. In distinguishing benign and malignant lesions, which constitutes this study, HBME-1, CK19, galectin-3 and TROP-2 were statistically significant (p < 0.001). In distinguishing cases of follicular variant papillary carcinoma from follicular nodular diseases and follicular adenoma, HBME-1 and galectin-3 were statistically significant (p < 0.001). Consequently, in this study, we found that all immunohistochemical markers were effective in distinguishing benign and malignant thyroid lesions. In determining malignancy, HBME-1 had the highest diagnostic accuracy, while CK19 was the most sensitive marker. The sensitivity increased when the markers were used together.

show abstract

A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo

Cited by 75 publications

References 40 publications

ROR1 expression correlated with poor clinical outcome in human ovarian cancer

ROR1 expression correlated with poor clinical outcome in human ovarian cancer

High Rab27A expression indicates favorable prognosis in CRC

Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19

Contact Info

Product

Resources

About